# Xinkanghe

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xinkanghe

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.kanovabiopharma.com
- Total disclosed funding: $30M
- Latest round: Series B (Jul 25, 2023)
- Investors on record: 12

## About

Established in 2015 and based in Suzhou, China, Xinkanghe is a biotechnology company that engages in drug research and development. The company's CSO, Dong Chen, is the founding dean of Shanghai Institute of Immunotherapy Innovation and a professor of Tsinghua University School of Medicine. Its first antibody drug for the treatment of autoimmune diseases received clinical trial approvals in February 2020. In November 2018, Xinkanghe raised CNY 115 million of series A funding led by new investor Northern Light Venture Capital, with participation from returning investors Bio Venture, BOHE Angel Fund and new investor Suzhou Kington Capital. In July 2023, Xinkanghe raised over CNY 100 million in series B+ funding led by new investor GTJA Investment Group. Other new investors Beijing Life Science Park Innovation Investment Fund,Hainan Orient Fenghai Private Equity Fund Management,Sanhetai Private Equity and returning investors CD Capital, Lotus Lake Capital, and Northern Light Venture Capital also participated in the round. The round was part of a larger CNY 100 million series B funding.
 
The company focuses on the development of new targets or innovative combinations of drugs for oncology and autoimmune inflammatory diseases, leading the way in the development of innovative immunotherapeutic antibodies.

## Funding rounds

- Series B, Jul 25, 2023, $14M — NLVC, GTJA Investment Group, Lotus Lake Capital, CD Capital, Beijing Life Science Park Innovation Investment Fund, Hainan Orient Fenghai Private Equity Fund Management, Sanhetai Private Equity
- Series B, Jul 13, 2021 — Oriza Holdings, Lotus Lake Capital, CD Capital, 3H Health Investment
- Series A, Nov 26, 2018, $17M — NLVC, YuanBio Venture, Kington Capital, Bohe Angel Fund

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A, Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series A
- Bohe Angel Fund — Series A
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B
- CD Capital — Series B
- 3H Health Investment (https://capitalatlas.ai/funds/3h-health-investment) — Series B
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series B
- Beijing Life Science Park Innovation Investment Fund — Series B
- Hainan Orient Fenghai Private Equity Fund Management — Series B
- Sanhetai Private Equity — Series B